Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.3K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

5.0K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
5.0K
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

3.0K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
3.0K
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

35
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
35
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.6K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic crosstalk between carbachol, a muscarinic receptor agonist, and the long-acting β<sub>2</sub>-adrenoceptor agonist, indacaterol, in human airway epithelial cells.

The Journal of pharmacology and experimental therapeutics·2025
Same author

Cyclic nucleotide phosphodiesterases as drug targets.

Pharmacological reviews·2025
Same author

A PDE4 shortform degrader: a first in isoform-specific PDE4 inhibition.

The FEBS journal·2025
Same author

Comparison of the Genomic Activity of an EP<sub>4</sub>-Receptor and β<sub>2</sub>-Adrenoceptor Agonist in BEAS-2B Human Bronchial Epithelial Cells: In Search of Compartmentalized, cAMP-Dependent Gene Expression.

The Journal of pharmacology and experimental therapeutics·2024
Same author

The β-Blocker Carvedilol and Related Aryloxypropanolamines Promote ERK1/2 Phosphorylation in HEK293 Cells with <i>K</i> <sub>A</sub> Values Distinct From Their Equilibrium Dissociation Constants as <i>β</i> <sub>2</sub>-Adrenoceptor Antagonists: Evidence for Functional Affinity.

The Journal of pharmacology and experimental therapeutics·2023
Same author

Phosphodiesterase 4 activity uniquely regulates ciliary cAMP-dependent 3T3-L1 adipogenesis.

Cellular signalling·2023

Related Experiment Video

Updated: Apr 30, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

42.1K

Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease.

Mark A Giembycz1, Donald H Maurice2

  • 1Department of Physiology & Pharmacology, Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Alberta, Canada.

Current Opinion in Pharmacology
|May 10, 2014
PubMed
Summary

Newer drugs targeting cyclic AMP (cAMP) pathways offer improved treatments for chronic obstructive pulmonary disease (COPD). These agents enhance airway smooth muscle relaxation and reduce inflammation, potentially increasing therapeutic effectiveness through synergistic interactions.

More Related Videos

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

10.7K
Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

9.9K

Related Experiment Videos

Last Updated: Apr 30, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

42.1K
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

10.7K
Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

9.9K

Area of Science:

  • Pulmonary Medicine
  • Pharmacology
  • Molecular Biology

Background:

  • Chronic obstructive pulmonary disease (COPD) involves progressive airflow limitation and airway inflammation.
  • Current COPD treatments include beta-agonists and roflumilast, acting via cyclic AMP (cAMP).
  • These drugs relax airway smooth muscle and reduce inflammation through cAMP-mediated pathways.

Purpose of the Study:

  • To review the pharmacology of novel agents targeting cAMP-mediated pathways in COPD.
  • To explore the potential for drug interactions to enhance therapeutic effectiveness.
  • To discuss the molecular mechanisms underlying these treatments.

Main Methods:

  • Literature review of existing and emerging COPD pharmacotherapies.
  • Analysis of molecular targets and signaling pathways, including cAMP effectors.
  • Pharmacological profiling of new agents and their potential interactions.

Main Results:

  • Established COPD drugs primarily target beta-adrenoceptors and phosphodiesterase 4.
  • Novel agents acting on cAMP-dependent protein kinase and exchange proteins activated by cAMP are emerging.
  • Potential for synergistic effects exists when combining agents that modulate these cAMP pathways.

Conclusions:

  • Emerging pharmacotherapies targeting cAMP pathways show promise for COPD management.
  • Understanding molecular interactions is key to optimizing treatment strategies.
  • Further research into combination therapies could significantly improve patient outcomes.